Skip to content

Public FDA record

Z-1436-2021: DirectInject consists of a sterile dual paste system which is calcium phosphate based. Upon injection thr

Recall record Z-1436-2021 for Stryker Leibinger GmbH & Co. KG. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1436-2021
Company in FDA record
Stryker Leibinger GmbH & Co. KG
FDA record creation date
Apr 19, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Inability for the user to inject the paste from the syringe into the target location.

Source facts

Action
On 04/01/2021, Stryker issued an Urgent Medical Device Removal notice via letter informing customers that users have reported the inability to push the paste through the Mixer-Cannula which prohibits the injection into a bone void.
Initiated
2021-04-01
Root cause
Under Investigation by firm
Terminated
2022-12-19
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Germany, Italy, France, Australia, Japan.
Recall number
Z-1436-2021
Recall status
Terminated
CDRH record ID
186761
FDA record created
2021-04-19
Recall event number
87684

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗